Estonian national focal point
The national focal point is located within the Centre for Drugs and Addictions of the National Institute for Health Development. The centre collects, harmonises and analyses data on drugs in Estonia, and disseminates information and cooperates with EU and non-EU national focal points, and other international bodies and organisations.
The Estonian national focal point was EMCDDA/EUDA assessed in September 2023.
News
Events
Publications
Publications related to this partner
This report explains how the Reitox Alliance and the European Union Drugs Agency (EUDA) will work together under the Agency’s new mandate.
This threat assessment examines the evolving presence and impact of highly potent synthetic opioids, particularly the group of 2-benzylbenzimidazole opioids (the so-called ‘nitazenes’) and carfentanil, in Estonia, Latvia and Lithuania.
This data factsheet presents insights from the European Web Survey on Drugs 2024. It provides an overview of key data from 61 732 individuals aged 18 or older who use drugs and live in one of 24 EU countries or Norway.
This page draws on the latest data available to provide an overview of the current situation and emerging drug issues affecting Europe, with a focus on the year up to the end of 2024.
Harm reduction encompasses interventions, programmes and policies that seek to reduce the health, social and economic harms of drug use to individuals, communities and societies. On this page, you can find the latest analysis of harm reduction interventions in Europe, including key data on o
Opioid users represent the largest group undergoing specialist drug treatment, mainly in the form of opioid agonist treatment.
Document library
Media library
Related photos, infographics and videos from our Media library
Contact information
National Institute for Health Development
Ms Katri Abel-Ollo
Tallinn
Estonia